EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations

Seok Kyeong Oh, Byung Gun Lim

Anesthesia and Pain Medicine · 31.01.2023 · 18 (1) · 11-20

DOI: 10.17085/apm.22259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anesthesia and Pain Medicine, erschienen am 31.01.2023. Verfasst von Seok Kyeong Oh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Seoul, Korea. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to unknown safety concerns, sugammadex should not be administered to patients with end-stage renal disease (ESRD). However, because the supply of benzylisoquinolinium-type neuromuscular blocking agents (NMBAs) has been discontinued, rocuronium is the only non-depolarizing NMBA that can be used in clinical settings in some countries, including South Korea. The administration of sugammadex cannot be avoided to achieve rapid and complete neuromuscular recovery in patients with ESRD or renal transplantation after rocuronium administration. Although there has been a limited number of clinical studies involving the use of sugammadex in patients with ESRD, studies have shown that sugammadex can effectively and safely reverse rocuronium-induced neuromuscular blockade (NMB) in patients with ESRD, however recovery of neuromuscular function in patients with ESRD is slower than in patients with normal renal function. Nonetheless, safety-concerns are yet to be addressed. Considering the small number of clinical studies, high heterogeneity among studies, and insufficient safety information, more extensive data on the efficacy and safety of sugammadex in patients with ESRD are needed. In particular, it is important to secure data on safety, including residual NMB after surgery, recurarization and cardiorespiratory complications, anaphylactic reactions, and long-term morbidity and mortality. Furthermore, anesthesiologists should remember that performing proper quantitative neuromuscular monitoring and neuromuscular management based on the monitoring signs are the most essential requirements when using sugammadex in patients with ESRD.

Schlagwörter

Stichwörter der Autor:innen

Chronic kidney failureDrug-related side effects and adverse reactionsEndstage renal diseaseNeuromuscular blockadeRocuroniumSugammadex

Autor:innen und Institutionen

  • Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Seoul, Korea.

Zitieren

APA

Oh, S. K., & Lim, B. G. (2023). Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations. Anesthesia and Pain Medicine, 18(1), 11-20. https://doi.org/10.17085/apm.22259

Vancouver

Oh SK, Lim BG. Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations. Anesthesia and Pain Medicine. 2023;18(1):11-20. doi:10.17085/apm.22259

BibTeX
@article{Oh2023,
  author = {Oh, Seok Kyeong and Lim, Byung Gun},
  title = {Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations},
  journal = {Anesthesia and Pain Medicine},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {11--20},
  doi = {10.17085/apm.22259}
}
Kostenlos starten →